

Galvanize Presents Preclinical Data on Aliya PEF in Combination with anti-PD1 in a Murine Triple Negative Breast Cancer Model at the 2023 American Society of Clinical Oncology Meeting

CHICAGO, Illinois, June 5, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a commercial-stage biomedical platform company operating at the convergence of engineering, biology and healthcare delivery, today announced promising preclinical data presented at the American Society of Clinical Oncology conference in Chicago using its Aliya™ Pulsed Electric Field (PEF) system in combination with an anti-PD1 immune checkpoint inhibitor drug in EMT6, a murine triple negative breast cancer model.

In the study, mice were implanted with EMT6 cells into the mammary fat pads. After tumors reached the target size, they were treated with anti-PD1 drug, either intraperitoneally or intratumorally. Other groups of animals received anti-PD1 drug intraperitoneally or intratumorally in combination with Aliya PEF, and another group received PEF twice at day 0 and day 7 in combination with intratumor anti-PD1.

The results demonstrated that Aliya PEF acted synergistically with the anti-PD1 treatment, reducing the tumor growth by 83% and 73% when combined with PEF for intratumor and intraperitoneal drug delivery, respectively. The animals treated twice with PEF and intratumor immunotherapy survived much longer, with 71% alive at day 65 versus 12.5% of those treated once with PEF and intratumor anti-PD1. Flow cytometric analysis confirmed that T cells, B cells and Natural Killer cells were all increased in the PEF groups as compared to controls, demonstrating the unique response of innate and adaptive immunity to the energy.

Dr. Mohit Trikha, Venture Partner at ATP and a Director on the Board of Directors at Galvanize Therapeutics, commented: "Having come from pharma and biotech, I have been continuously enthused that Aliya, a medical device, is showing evidence of generating potent neoantigenicity in preclinical models. Now that it has been shown to synergize with immune checkpoint inhibitors, we are even more excited to bring the system into the clinic to study its utility in the majority of patients who fail to demonstrate a response to these medications when used alone."

"We are thrilled to be one of the few medical device companies presenting data at the ASCO conference, demonstrating our commitment to investigating the mechanisms of action of the Aliya system," said Jonathan Waldstreicher, M.D., Founder and CEO of Galvanize Therapeutics. "Our Aliya clinical program is just as robust as our preclinical research with five clinical studies ongoing to study the Aliya system in various soft tissue and tumor targets. We look forward to presenting more clinical data as it becomes available."

About Aliya™ PEF System

The Aliya PEF system delivers high-voltage, high-frequency electrical currents through a single monopolar electrode placed in the target tissue. The PEF energy destabilizes the cells via electric fields, resulting in non-thermal cell death.

The Aliya PEF system preserves surrounding healthy tissue, enabling non-thermal ablation near critical structures, such as nerves and blood vessels. The Aliya waveform and electrode are designed to maximize the potential for releasing tumor antigens and may stimulate an immune response, potentially disrupting the immunosuppressive tumor microenvironment.

The Aliya System is 510(k) cleared in the United States for the surgical ablation of soft tissue. It is not currently commercially available in any other geography.

About Galvanize Therapeutics™

Galvanize Therapeutics aims to become the global leader in delivering medical technology innovations that drive biologic processes to treat a range of diseases, starting with treating chronic bronchitis symptoms, cardiac arrhythmias, and solid tumors. Formed by ATP (Apple Tree Partners) in 2022, Galvanize is based in San Carlos, Calif., and is researching and commercializing its revolutionary Aliya Pulsed Electric Field (PEF) energy platform in the United States and Europe. For more information, please visit www.galvanizetx.com.

About ATP

Founded in 1999, Apple Tree Partners (ATP) is a leader in life sciences venture capital, with \$2.65 billion in committed capital and offices in New York, London, San Francisco, and Cambridge, MA. ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond. The core of ATP's strategy is providing flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that deliver therapeutics to improve human lives. For more information, visit www.appletreepartners.com.

SOURCE Galvanize Therapeutics, Inc.